Renal cell carcinoma and the WNT/ β-catenin pathway

The highly conserved WNT pathway is involved in the transduction of signals from the cell surface to the nucleus, and it is known to play a key role in embryonic development, adult tissue maintenance and tumourigenesis (Klaus &Birchmeier, 2008). 11/11/2012
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news

Related Links:

CD8+ T cells stimulated by exosomes derived from RenCa cells mediate specific immune responses through the FasL/Fas signaling pathway and, combined with GM‑CSF and IL‑12, enhance the anti‑renal cortical adenocarcinoma effect. Oncol Rep. 2019 Jun 20;: Authors: Xu HY, Li N, Yao N, Xu XF, Wang HX, Liu XY, Zhang Y Abstract A satisfactory cure rate for renal cell carcinoma (RCC) is difficult to achieve through traditional immunotherapy. RCC has a relatively high spontaneous regression rate due to tumor immune escape. However, tumor‑derived exosomes (TEXs), which effectively carry tumor‑associ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Targeted therapies were associated with"modest survival advantages" in elderly Medicare patients with metastatic renal cell carcinoma (mRCC) in a retrospective study.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
This review focuses on what is the biological basis of esophageal cancer for immunotherapy, how to screen out the patients who can benefit from immunotherapy, and whether the toxic side effects of immunotherapy are manageable. AbstractConsidering the benefits of immunotherapy in advanced melanoma, non –small cell lung cancer, renal cell carcinoma, bladder cancers, and refractory Hodgkin lymphoma, we begin to consider whether immunotherapy is effective for esophageal cancer, which is extremely malignant and has a poor prognosis. There are a large number of clinical trials to study the applicatio n of immunotherapy suc...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: REVIEW Source Type: research
We describe common side effects of this treatment, and advise how they are best prevented and managed.
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionRF ablation, cryoablation, and MW ablation are equivalent at 2 years for treatment of T1a RCC for therapeutic outcome, stability of renal function, and low adverse event rate.
Source: Journal of Vascular and Interventional Radiology - Category: Radiology Source Type: research
FRIDAY, June 21, 2019 -- Prospective validation of existing renal cell carcinoma (RCC) prediction models demonstrates a decrease in their predictive ability, according to a study published online June 19 in the Journal of Clinical Oncology. Andres...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
ConclusionsTo the best of our knowledge, renal malignancy presenting as syndrome of inappropriate antidiuretic hormone secretion and Leser –Trélat concurrently is rare. The causes of hyponatremia in the elderly, approach to investigation, and value as a poor prognostic marker in malignancy are highlighted. We also discuss Leser–Trélat syndrome, its pathophysiology, and its possible implications on clinical practice.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
(University of Pennsylvania School of Medicine) Many elderly patients with metastatic renal cell carcinoma (RCC) -- who are often underrepresented in clinical trials to treat the kidney cancer -- are seeing overall survival benefits from treatment with targeted therapies, according to a new study published in JAMA Network Open.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
AbstractRenal cell carcinoma (RCC) is one of the most lethal urologic malignancies. Its incidence continues to rise worldwide with a rate of 2% per year. Approximately, one-third of the RCC patients are diagnosed at advanced stages due to the asymptomatic nature of its early stages. This represents a great hurdle, since RCC is largely chemoresistant/radioresistant, and targeted therapy of mRCC still has limited efficacy. The 5-year survival rate of metastatic RCC (mRCC) is only around 10%. Adoptive cell transfer (ACT), a particular form of cell-based anticancer immunotherapy, is a promising approach in the treatment of mRC...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
AbstractTumor-associated macrophages have been well-characterized in solid malignancies, including renal cell carcinoma and generally correlate with poor prognosis. However, the molecular mechanisms which govern intratumoral macrophage behavior and patient outcome are unclear. Here, we investigated whether alterations in macrophage expression of the transcriptional regulator for myeloid commitment and function, interferon regulatory factor-8 (IRF8), could predict survival of clear cell renal cell carcinoma patients. Transcriptional analysis of publicly available data revealed elevated IRF8 expression was associated with pr...
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Renal Cell Carcinoma | Urology & Nephrology